Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding
Lee A. Denson, … , Carol R. Williams, Saul J. Karpen
Lee A. Denson, … , Carol R. Williams, Saul J. Karpen
Published June 1, 2001
Citation Information: J Clin Invest. 2001;107(11):1451-1458. https://doi.org/10.1172/JCI10994.
View: Text | PDF
Article

TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding

  • Text
  • PDF
Abstract

Children with chronic inflammatory diseases experience growth failure and wasting. This may be due to growth hormone resistance caused by cytokine-induced suppression of growth hormone receptor (GHR) gene expression. However, the factors governing inflammatory regulation of GHR are not known. We have reported that Sp1 and Sp3 regulate hepatic GHR expression. We hypothesized that TNF-α suppresses GHR expression by inhibiting Sp1/Sp3 transactivators. LPS administration significantly reduced murine hepatic GHR expression, as well as Sp1 and Sp3 binding to GHR promoter cis elements. TNF-α was integral to this response, as LPS did not affect hepatic Sp1/Sp3 binding or GHR expression in TNF receptor 1–deficient mice. TNF-α treatment of BNL CL.2 mouse liver cells reduced Sp1 and Sp3 binding to a GHR promoter cis element and downregulated activity of a GHR promoter-driven luciferase reporter. Combined mutations within adjacent Sp elements eliminated GHR promoter suppression by TNF-α without affecting overall nuclear levels of Sp1 or Sp3 proteins. These studies demonstrate that murine GHR transcription is downregulated by LPS, primarily via TNF-α–dependent signaling. Evidence suggests that inhibition of Sp transactivator binding is involved. Further investigation of these mechanisms may identify novel strategies for preventing inflammatory suppression of growth.

Authors

Lee A. Denson, Ram K. Menon, Angel Shaufl, Himmat S. Bajwa, Carol R. Williams, Saul J. Karpen

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Sp1 and Sp3 bind the L2 GHR promoter via adjacent response elements. EMS...
Sp1 and Sp3 bind the L2 GHR promoter via adjacent response elements. EMSA was performed using nuclear proteins from (a) adult mouse liver or (b and c) BNL CL.2 mouse liver cells and radiolabeled L2A or L2B elements. Supershift (a and b) or immunodepletion (c) with Sp1, Sp3, IgG, or STAT1 antibodies was performed. (c) EMSA for nuclear extracts that were immunodepleted using Sp1, Sp3, or control IgG antibodies before EMSA with the L2A element is shown on the left. Immunoblots confirming specific Sp1 or Sp3 depletion in these extracts are shown on the right. Ab: antibody used for immunodepletion; I: L2A or L2B complex containing both Sp1 and Sp3 proteins; II: L2A or L2B complex containing only Sp3; IIIA or IIIB: faster migrating complexes — L2A or L2B, respectively — which do not contain Sp1 or Sp3; HNF1: HNF1 consensus oligonucleotide.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts